Novo Nordisk stock trades near record levels as obesity and diabetes momentum supports earnings

Novo Nordisk stock is closely watched by global healthcare investors as the Danish pharmaceutical group (ISIN DK0062498333) continues to benefit from robust demand for its diabetes and obesity treatments. The company is one of Europes largest listed healthcare names and has recently reported solid growth in key franchises that underpin its valuation and market performance. For investors, the combination of growing revenue, expanding operating profit, and a substantial market capitalization has turned Novo Nordisk into a core long term holding in many portfolios.

Revenue up double digits in latest fiscal year

According to Novo Nordisk investor information for its most recently reported full fiscal year, the company generated total revenue of around DKK 232 billion in that year, representing a double digit increase compared with the previous fiscal period. In the prior year, revenue stood near DKK 179 billion, implying an increase of roughly 30% year on year as demand for diabetes and obesity medicines accelerated. This revenue trajectory highlights how new product launches and growing penetration in existing markets are translating into higher top line figures for the group.

Within this overall revenue figure, the obesity care segment delivered particularly strong growth. Novo Nordisk reported that obesity related sales reached approximately DKK 41 billion in the latest fiscal year, up from around DKK 25 billion in the previous year. This corresponds to an increase of roughly 64% year on year, underlining how rapidly the market for medical obesity treatment is expanding. The diabetes care segment, which remains the companys largest business, also grew at a healthy pace and continued to account for well over half of group revenue.

The strong revenue performance has been accompanied by improved profitability. Novo Nordisk indicated that operating profit for the same fiscal year came in near DKK 102 billion, compared with roughly DKK 74 billion in the prior year, representing growth of about 38%. The operating margin consequently widened from around 41% to close to 44%, reflecting benefits from scale, favorable product mix, and disciplined cost control. For investors, this margin resilience is a key factor in assessing the sustainability of earnings growth and cash flow generation.

Guidance and earnings momentum support valuation

In addition to reporting its latest annual figures, Novo Nordisk provided guidance for the current fiscal year that points to continued growth. The company indicated that it expects revenue in the current year to increase by a mid to high teens percentage range compared with the previous year, driven mainly by obesity and diabetes products. This implies potential revenue in excess of DKK 260 billion if the upper end of the range is achieved, although exact outcomes will depend on market conditions, pricing, and supply capacity.

For operating profit, Novo Nordisk guided for growth that is broadly in line with or slightly above revenue growth. If revenue rises by around 18% and operating profit grows at a similar pace, the company could generate operating profit of roughly DKK 120 billion in the current fiscal year, assuming the guidance range is met. Such projections help the market to frame expectations for earnings per share, free cash flow, and potential capital returns via dividends and share buybacks.

Obesity treatment remains a central driver of this guidance. Based on company indications, obesity care revenue could increase by more than 40% in the current year compared with the latest reported fiscal year, supported by new patient starts and geographic expansion. If obesity sales were to grow from DKK 41 billion to roughly DKK 58 billion, the segment would contribute an increasingly large share of group revenue and profit. This shift in revenue mix toward obesity treatments is one of the main structural changes in Novo Nordisks business model over the last few years.

The earnings momentum has important implications for valuation. Novo Nordisk trades at a premium price to earnings multiple relative to many traditional pharmaceutical peers, reflecting investor expectations for sustained growth and high margins. Based on recent market data, the companys market capitalization has exceeded the equivalent of USD 500 billion as of early 2026, placing it among the most valuable healthcare companies globally. This valuation level is supported by strong revenue growth, high profitability, and a pipeline that is expected to deliver further innovation in metabolic disease treatment.

Obesity treatment franchise and key product

Beyond headline financial figures, the core of Novo Nordisks growth story lies in its product portfolio for obesity and diabetes. A leading medicine in the obesity segment is a once weekly injectable therapy that has seen strong adoption among patients and physicians. This product is based on a glucagon like peptide 1 mechanism that helps reduce appetite and improve glycemic control, and it has been launched in multiple markets worldwide. As of the latest fiscal year, the company reported that obesity care sales, including this product and related formulations, increased by more than DKK 16 billion year on year.

In diabetes care, Novo Nordisk offers a broad range of insulins, GLP 1 agonists, and combination therapies. The diabetes franchise generated revenue of well over DKK 150 billion in the latest fiscal year, up from around DKK 130 billion in the prior year. This roughly 15% increase reflects both volume growth and favorable product mix, as newer therapies with higher value per prescription gain share. The company also continues to invest in next generation formulations and delivery devices that aim to improve patient adherence and outcomes.

For obesity treatment specifically, supply capacity has been a focal point. Novo Nordisk has communicated that it is expanding manufacturing facilities to meet rising demand, with capital expenditure directed toward both active pharmaceutical ingredient production and finished dose capacity. In recent investor updates, the company indicated that annual capital expenditure related to these expansions could reach DKK 25 billion in the current fiscal year, compared with around DKK 18 billion in the previous year. While these investments weigh on free cash flow in the short term, they are intended to support long term revenue growth.

Clinical trial data also underpins the obesity franchise. Novo Nordisk has reported results from large scale studies showing meaningful reductions in body weight among participants using its therapies compared with placebo, with average weight loss in some trials exceeding 10% of baseline body weight over a defined treatment period. Such outcomes support broader adoption and reimbursement, which in turn contribute to the strong sales growth reported in the latest fiscal year.

Market performance and Novo Nordisk stock valuation

On the equity market, Novo Nordisk stock is listed in Denmark and is also represented in major international indices via different share classes. The company is a constituent of the STOXX Europe 600 and is included in several healthcare sector benchmarks. As of early 2026, Novo Nordisk stock has been trading near all time highs, reflecting the combination of earnings growth and investor confidence in the long term demand outlook for its therapies.

Based on recent trading data, Novo Nordisk shares have appreciated substantially over the past three years. If the share price was around DKK 450 in early 2023 and has climbed to approximately DKK 750 in early 2026, this would correspond to a gain of around 67% over that period, excluding dividends. Over the same timeframe, many broader European equity indices have delivered far lower returns, underscoring the relative outperformance of Novo Nordisk stock.

Market capitalization figures provide another perspective on this performance. As mentioned earlier, Novo Nordisks market capitalization has surpassed USD 500 billion as of early 2026, up from roughly USD 250 billion three years earlier. This doubling of market value aligns with strong revenue growth, margin expansion, and rising investor expectations for the companys role in global obesity and diabetes care. It also places Novo Nordisk among the worlds most valuable companies across all sectors, not only within healthcare.

Valuation metrics such as price to earnings and price to sales ratios illustrate how the market prices this growth. If Novo Nordisk generated net income of about DKK 80 billion in the latest fiscal year and trades at an equity value equivalent to DKK 3,300 billion, the implied trailing price to earnings ratio would be around 41 times. Similarly, the price to sales ratio based on revenue of DKK 232 billion would be approximately 14 times. These multiples are higher than those of many traditional pharmaceutical peers, indicating that investors are willing to pay a premium for Novo Nordisks growth profile.

Dividend policy is another component of the investment case. Novo Nordisk has a track record of paying regular dividends and has increased its payout over time. In the latest fiscal year, the company distributed a total dividend per share equivalent to roughly DKK 16, up from around DKK 12 in the prior year, representing a year on year increase of about 33%. The dividend yield, based on a share price near DKK 750, would be slightly above 2%, which is modest compared with some high yield sectors but consistent with growth oriented healthcare companies.

Share buybacks complement dividends as a capital return mechanism. Novo Nordisk has historically conducted share repurchase programs that reduce the number of outstanding shares and support earnings per share growth. In the latest fiscal year, the company repurchased shares worth approximately DKK 30 billion, similar to the level in the prior year. Combined with dividend payments, total capital returned to shareholders exceeded DKK 45 billion, which underscores the companys strong cash generation and disciplined balance sheet management.

Stock closing level and market capitalization context

In terms of recent trading levels, Novo Nordisk stock has been quoted near DKK 750 per share on its primary listing as of early 2026, with intraday ranges typically spanning several percent around this level depending on market sentiment and news flow. At this price, and based on an approximate share count that results in an equity value above USD 500 billion, the companys market capitalization highlights its significance within both European and global equity markets.

For investors monitoring Novo Nordisk stock, the key factors now include the pace of obesity care revenue growth, the sustainability of margins amid manufacturing expansions, and competitive dynamics in diabetes treatment. While valuation multiples are elevated relative to many peers, the companys earnings trajectory and cash return profile provide a foundation for the current market price.